Introduction {#sec1_1}
============

Chronic kidney disease (CKD) is an independent risk factor for cardiovascular disease and is associated with increased cardiovascular morbidity and mortality \[[@B1]\]. Identiﬁcation of patients at risk could alert physicians to monitor cardiovascular risk and implement the control of the aggressive risk factors.

A fragmented QRS complex (fQRS) is a bunch of electrocardiographic signals that show ventricular conduction delays in scarred myocardial regions \[[@B2]\]. The presence of fQRS complexes had been found to be associated with all-cause mortality and recurrent cardiac events \[[@B3]\]. fQRS had been shown as a highly sensitive and specific marker of myocardial scar \[[@B4]\].

Arterial stiffness is a measure of how the large arteries react to changes in blood pressure, and it is an important marker for endothelial dysfunction and atherosclerosis. Arterial stiffness increase is shown to be related with left ventricular (LV) diastolic dysfunction \[[@B5]\]. Aortic stiffness and LV diastolic dysfunction basically share a common etiological mechanism that includes tissue fibrosis. Myocardial fibrosis and scar result in deterioration of LV activities. It had been shown that inhomogeneous LV activity is related to fQRS formation in electrocardiography \[[@B6]\]. Korkmaz et al. \[[@B6]\] had shown the relation between aortic stiffness and fQRS in asymptomatic hypertensive patients. Although fQRS is known to be associated with increased cardiovascular morbidity and mortality, its role in predicting subclinical heart damage and effects on diastolic dysfunction and aortic stiffness has not been reported previously in hemodialysis patients. Hence, this study aimed to evaluate the relation among fQRS, diastolic dysfunction, and aortic stiffness in patients with CKD by using echocardiography and electrocardiography (ECG).

Materials and Methods {#sec1_2}
=====================

Patient Selection {#sec2_1}
-----------------

Fifty-Six consecutive patients with CKD who had undergone hemodialysis treatment 3 times a week for at least 1 year in Ahi Evran University Medical Faculty from June 2014 to April 2015 were recruited into this study. Exclusion criteria were active infections, bundle-branch block (left bundle-branch block, incomplete or complete right bundle-branch block) or intraventricular conduction delay (duration of QRS \>120 ms) on ECG, permanent pacemakers, significant stenosis by fractional flow reserve measurement, history of percutaneous or surgical revascularization, moderate to severe valve disease, LV dysfunction (ejection fraction \<40%), liver failure, atrial fibrillation, congenital heart disease, systemic conditions (ankylosing spondylitis, rheumatoid arthritis, Marfan and Ehlers-Danlos disease), and aortic aneurysms. The 56 patients were stratified into 2 groups according to their ECG patterns with (group 1; *n* = 26) or without fQRS (group 2; *n*= 30). Systolic and diastolic blood pressures were measured in each individual twice, following a 5-min rest, with an Erka brand sphygmomanometer using an appropriate cuff width. Fifteen patients who were on hypertension medication were recorded. The protocol was approved by the institutional review boards of the Faculty of Medicine, Pamukkale University, Denizli, Turkey, and adhered to the Declaration of Helsinki. Patients were informed about the study, and written consent was obtained from all subjects.

Biochemical Analysis {#sec2_2}
--------------------

A 5-mL blood sample was taken just before hemodialysis treatment following 12 h of fasting. Complete blood count measurement was made using flow cytometry, fasting blood glucose, creatinine, albumin, and serum lipid measurements with an enzymatic colorimetric method, C-reactive protein measurements were done using an immunoturbidimetric method, and sodium, potassium, and chloride measurements were made with an ion-selective electrode method. A Sysmex XT 2000I device was used for complete blood count, and the other biochemical parameters were studied using the Modular P Roche/Hitachi device.

Measurement of fQRS {#sec2_3}
-------------------

fQRS was defined as presence of at least 1 of the following findings in 12-lead routine ECG before dialysis: presence of an additional R wave (R\'), notching of R or S wave, or \>1 R\' fragmentation in 2 contiguous leads \[[@B7]\]. The ECGs were analyzed by 2 independent cardiologists (G.N., A.İ.) blinded to the patient characteristics.

Echocardiographic Data {#sec2_4}
----------------------

Echocardiography was performed in the patients approximately 1 h before dialysis after a 15-min rest. The entire study population of the 56 patients underwent screening by 2-dimensional echocardiography, which consisted of conventional Doppler sonography via a standard 2-dimensional transducer device (Vingmed System Vivid 5; GE Vingmed Ultrasound, Horten, Norway); images were obtained in the left lateral decubitus position. LV filling was evaluated by pulse wave Doppler sonography, from the apical 4-chamber view, with the sample volume positioned at the tips of the mitral valve. We recorded the early (E)/late (A) ventricular filling velocity (E/A) ratio, isovolumic relaxation time (IVRT), and E wave deceleration time (DT), together with early and late diastolic velocities. Tissue Doppler imaging utilizes modified wall filter and reduced gain in order to display myocardial velocity while avoiding blood flow detection. From the 4-chamber view, the tissue Doppler imaging sample volume was placed sequentially at septal and lateral sides of the valvular ring. The mean early (Em) diastolic, late diastolic, and systolic myocardial velocities were calculated (cm/s). Furthermore, we measured the E/Em ratio. All measurements were done at 50 m/s at the end of the expiration. The modified Simpson method was used to calculate LV ejection fraction.

The M-mode rod was placed so that it could pass through the aortic region that was 3 cm distal to the aortic valve. Systolic and diastolic diameters of the ascending aorta were obtained from the aortic trace. Systolic diameter was measured from the location of the aortic trace in which the maximum forward movement was observed, while diastolic diameter was measured from the location that corresponded to the R spike of the ECG. To determine the pulse pressure, which was necessary for the calculation of relevant parameters, the systolic blood pressure and diastolic blood pressure were concurrently measured with a mercury sphygmomanometer. The difference between the 2 blood pressure values was accepted as the pulse pressure. Average systolic and diastolic measurements were calculated following 3 consecutive measurements. The aortic elastic properties were calculated by using the formulae below:
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Statistical Analysis {#sec2_5}
--------------------

The continuous variables are expressed as means ± SD, whereas categorical variables are percentages. *p* \< 0.05 was statistically significant. Parametric continuous variables were compared by the independent Student *t* test or Mann-Whitney *U* test. Categorical variables were analyzed by the χ^2^ and Fisher exact tests. Spearman correlation was used for correlation analysis. Multiple regression analysis was made for the relation between fQRS and aortic stiffness. The statistical analyses were carried out with the Windows SPSS v17.0 package program.

Results {#sec1_3}
=======

There were no significant differences between patients with fQRS and without fQRS when they were evaluated for baseline characteristics such as etiology of CKD, medications, gender and age (Table [1](#T1){ref-type="table"}), and laboratory parameters (*p* \> 0.05; Table [2](#T2){ref-type="table"}).

Echocardiographic evaluation showed that diastolic parameters like early diastolic velocity (58.23 ± 19.96 m/s; *p* = 0.004), and Em (5.96 ± 2.08 cm/s; *p* = 0.023) levels were significantly low in hemodialysis patients with fQRS. DT (237.57 ± 40.10 ms; *p* = 0.030), IVRT (*p* \< 0.001), and E/A ratio (1.15 ± 0.40; p \< 0.001) values exhibited a statistical increase in hemodialysis patients with fQRS (Table [3](#T3){ref-type="table"}). There was a significant difference between the groups, and aortic elastic properties (Table [4](#T4){ref-type="table"}), aortic strain (5.66 ± 2.38%), and distensibility (2.63 ± 1.05 cm^2^ × dyn^-1^) were significantly lower in the fQRS group (*p* \< 0.01) patients. The aortic stiffness index (9.62 ± 4.53) was significantly higher in the fQRS group (p \< 0.01).

In this study, a statistically significant relationship was identified between aortic stiffness and diastolic dysfunction in hemodialysis patients (DT *r* = 0.273, *p* = 0.042; IVRT *r* = 0.497, *p* \< 0.001; E/A ratio *r* = −0.449, *p* = 0.001).

After adjusting the C-reactive protein value, disease duration of CKD and albumin in multiple regression analysis, fQRS was significantly correlated independently with aortic stiffness (β = 0.313, *p* = 0.048; 95% confidence interval: 0.19-5.33).

Discussion {#sec1_4}
==========

In this study, aortic stiffness increase and LV diastolic dysfunction were more common in hemodialysis patients with fQRS than patients without fQRS. fQRS and aortic stiffness were independently associated in hemodialysis patients. Also, it was shown that aortic stiffness increase was related to LV diastolic dysfunction.

The finding that LV diastolic dysfunction was severer in hemodialysis patients with fQRS than patients without fQRS confirmed that of Ulusoy et al. \[[@B8]\] who had demonstrated that fQRS was related with systolic and diastolic dysfunction of the left ventricle in kidney transplant patients. Also Adar et al. \[[@B9]\] showed that fQRS was independently associated with subclinical LV dysfunction in patients with CKD and normal ejection fraction. A probable cause of the relationship between diastolic function and fQRS could be myocardial fibrosis causing inhomogeneous activation and fQRS formation that causes diastolic dysfunction \[[@B8],[@B9],[@B10]\].

In this study the finding that an independent relationship exists between fQRS and aortic stiffness confirmed that the presence of fQRS reported by Korkmaz et al. \[[@B6]\] is associated independently with increased arterial stiffness in asymptomatic hypertensive patients. However, Ikonomidis et al. \[[@B11]\] reported the relationship between diastolic dysfunction and aortic distensibility in hypertensive patients, and also LV mass and function were reported to be related to aortic stiffness in previous studies \[[@B12],[@B13]\]. There are possible explanations for the relation between aortic distensibility and diastolic dysfunction. LV diastolic dysfunction and aortic stiffness may be epiphenomena of the myocardial and aortic injuries in hemodialysis patients \[[@B14]\]. The second possible explanation is that increased aortic stiffness may also increase afterload. An increase in afterload induces myocardial structural changes of the left ventricle and thus causes LV diastolic dysfunction \[[@B15]\]. Additionally, structural changes in left ventricle were suggested to be related with aortic stiffness \[[@B15],[@B16],[@B17]\].

Age is the main clinical marker in arterial stiffness. Aortic stiffness is identified to be 5-10% less in women. Also blood pressure and diabetes mellitus can affect aortic stiffness in kidney disease \[[@B18]\]. We did not observe any statistically significant differences between patients with and without fQRS in terms of age, gender, diabetes mellitus, blood pressure levels, chronic kidney failure duration and Kt/V value which shows adequateness of dialysis.

Conclusion {#sec1_5}
==========

In this study increased aortic stiffness and LV systolic dysfunction were observed more frequently in hemodialysis patients with fQRS than patients without fQRS. fQRS was related independently with aortic stiffness. Presence of fQRS can be used for risk stratification in hemodialysis patients.

###### 

Comparison of biochemical features of the hemodialysis patients

                                              Group 1             Group 2             *p* value
  ------------------------------------------- ------------------- ------------------- -----------
  Leukocytes, *n*/mm^3^                       7.61 ± 2.82         7.92 ± 3.51         0.764
  Hemoglobin, g/dL                            10.45 ± 1.71        11.07 ± 1.60        0.233
  Urea, mg/dL                                 151.63 ± 35.78      158.33 ± 29.05      0.800
  Creatinine, mg/dL                           8.33 ± 2.21         8.07 ± 2.54         0.722
  Albumin, mg/dL                              3.50 ± 0.27         3.56 ± 0.28         0.561
  Uric acid, mg/dL                            6.48 ± 1.00         6.40 ± 1.18         0.818
  Glucose, mg/dL                              108.30 ± 40.05      126.70 ± 48.59      0.140
  Ferritin, mg/dL                             1,013.45 ± 410.09   802.10 ± 404.79     0.109
  Total cholesterol, mg/dL                    169.09± 38.60       174.90 ± 41.88      0.638
  LDL, mg/dL                                  98.63 ± 27.22       105.95 ± 26.86      0.387
  HDL, mg/dL                                  34.41 ± 9.10        34.57 ± 8.71        0.953
  Triglyceride, mg/dL                         180.31 ± 83.28      191.66 ± 87.62      0.683
  Calcium, mg/dL                              9.16 ± 0.74         8.80 ± 0.60         0.887
  Phosphorus, mg/dL                           4.94 ± 1.29         4.71 ± 1.37         0.580
  CRP, mg/dL                                  2.63 ± 3.70         1.64 ± 2.61         0.320
  PTH, pg/mL                                  383.68 ± 441.61     217.95 ± 143.41     0.119
  UF, mL                                      2,938.88 ± 675.74   2,984.21 ± 857.81   0.860
  Duration of chronic renal failure, months   90.78 ± 67.96       74.28 ± 47.18       0.359
  Kt/V                                        1.49 ± 0.30         1.47 ± 0.18         0.800

Group 1: hemodialysis patients with fQRS; group 2: hemodialysis patients without fQRS; LDL, low-density lipoprotein; HDL, high-density lipoprotein; CRP, C-reactive protein; PTH, parathyroid hormone; UF, amount of liquid drawn in a single dialysis session; Kt/V, product of dialyzer urea clearance and treatment time divided by body urea volume.

###### 

Comparison of the clinical and demographic data in hemodialysis patients

                               Group 1         Group 2               ^*p*^ value
  ---------------------------- --------------- --------------------- -------------
  *Etiology of CKD, %*                                               
  Diabetes mellitus            42.3            36.7                  0.437
  Hypertension                 23.1            30.0                  0.391
  Glomerulonephritis           7.7             10.0                  0.569
  Nephrolithiasis              3.8             3.3                   0.718
  Unknown                      22.2            17.8                  0.788
                                                                     
  *Medications, %*                                                   
  Erythropoietin               38.5            36.7                  0.94
  Vitamin D                    26.9            33.3                  0.452
  β-Blockers                   11.5            20.0                  0.383
  ACE/ARB                      0.0             3.3                   0.253
  Antilipidemic agent          69.2            3.3                   0.536
  Ca-based phosphate binders   15.5            56.7                  0.245
  ACE                          50.0            20                    0.560
                                                                     
  *Demographics*                                                     
  Gender male, %               42.3            53.6                  0.508
  Age, years                   59.82 ± 13.98   66.23 ± 11.10 0.102   

Group 1: hemodialysis patients with fQRS; group 2: hemodialysis patients without fQRS; CKD, chronic kidney disease; ACE, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers.

###### 

The measurement of echocardiographic parameters in groups 1 and 2

                                      Group 1          Group 2           *p* value
  ----------------------------------- ---------------- ----------------- -----------
  LVEDD, mm                           46.30 ± 5.76     47.30 ± 5.25      0.504
  LVESD, mm                           31.26 ± 6.36     32.06 ± 5.87      0.628
  IVS thickness, mm                   15.03 ± 10.19    112.66 ± 1.76     0.215
  PW thickness, mm                    12.96 ± 1.75     4,912.66 ± 1.72   0.530
  LVEF, %                             57.11 ± 10.75    58.13 ± 7.58      0.681
  LA dimension, mm Aortic diastolic   41.88 ± 5.33     40.30 ± 5.01      0.257
  diameter, mm                        30.02 ± 4.18     30.01 ± 4.59      0.998
  E, m/s                              58.23 ± 19.96    78.83 ± 29.74     0.004
  A, m/s                              77.76 ± 17.34    73.03 ± 28.38     0.463
  DT, ms                              237.57 ± 40.10   212.73 ± 43.73    0.030
  IVRT, ms                            126.84 ± 15.62   107.30 ± 17.89    0.000
  Em, cm/s                            5.96 ± 2.08      7.63 ± 3.06       0.023
  E/A ratio                           1.15 ± 0.40      0.76 ± 0.26       0.000

Group 1: hemodialysis patients with fQRS; group 2: hemodialysis patients without fQRS; LVEDD, left ventricular end-diastolic dimension; LVESD, left ventricular end-systolic dimension; IVS, ventricular septum; PW, posterior wall; LVEF, left ventricular ejection fraction; LA, left atrium; E, early diastolic flow; A, atrial contraction signal; DT, deceleration time; IVRT, isovolumic relaxation time.

###### 

The measurement of aortic elastic properties in groups 1 and 2

                                    Group 1       Group 2       *p* value
  --------------------------------- ------------- ------------- -----------
  Aortic strain, %                  5.66 ± 2.38   7.64 ± 2.84   0.007
  Distensibility, cm^2^ × dyn^-1^   2.63 ± 1.05   3.58 ± 1.91   0.029
  Aortic stiffness index            9.62 ± 4.53   7.02 ± 3.23   0.016

Group 1: hemodialysis patients with fQRS; group 2: hemodialysis patients without fQRS.
